Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Statins may affect prostate cancer microenvironment

Allott E et al. AUA 2018 (annual meeting of the American Urological Association), Abstract MP21-01.

Key clinical point: Researchers hope that genetic analyses could eventually point to prostate cancer patients who might benefit from statin use.

Major finding: Long-term statin users had lower odds of having a pTEN-null tumor (hazard ratio, 0.42), which is associated with worse outcomes.

Study details: Retrospective analysis of 5,792 diagnoses of prostate cancer among 44,076 men.

Disclosures: The study was funded by the Irish Cancer Society, the John Fitzpatrick Fellowship, and the National Cancer Institute. Dr. Allott reported no relevant financial relationships.

Source: Allott E et al. AUA 2018, Abstract MP21-01.

Citation:

Allott E et al. AUA 2018 (annual meeting of the American Urological Association), Abstract MP21-01.

This Week's Must Reads

Liquid biopsy aids assessment in advanced imatinib-resistant GIST, George S et al. ASCO 2018. Abstract 11511.

Rapid therapy changes fall short for metastatic GIST, Serrano-Garcia C et al. ASCO 2018, Abstract 11510.

Estimated conditional OS shows upfront TKI benefit in mRCC, Kang M et al. J Urol. 2018 June 22. doi: 10.1016/j.juro.2018.06.030

Indolent course found in rare clear cell papillary RCC , Chen W-J et al. J Chinese Med Assoc. 2018 July 20 doi: 10.1016/j.jcma.2018.04.005

Must Reads in Genitourinary Cancer

Estimated conditional OS shows upfront TKI benefit in mRCC, Kang M et al. J Urol. 2018 June 22. doi: 10.1016/j.juro.2018.06.030

Indolent course found in rare clear cell papillary RCC , Chen W-J et al. J Chinese Med Assoc. 2018 July 20 doi: 10.1016/j.jcma.2018.04.005

Study: Clear cell papillary RCC has indolent course, Chen W-J et al. J Chinese Med Assoc. 2018 July 20 doi: 10.1016/j.jcma.2018.04.005

Combo therapy after disease progression no advantage in chemotherapy-naïve metastatic castration-resistant prostate cancer, Attard G et al. Journal of Clinical Oncology; published online 20 July 2018. http://ascopubs.org/doi/abs/10.1200/JCO.2018.77.9827

In metastatic hormone-sensitive prostate cancer, prior local therapy is linked to improved survival, Abdel-Rahman O and Cheung W. Clinical Genitourinary Cancer; published online 21 July 2018 https://doi.org/10.1016/j.clgc.2018.07.007